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Dysfunctionalmitochondriaareawell-knowndiseasehallmark.Theaccumulationofaberrantmitochondriacan
altercellhomeostasis,thusresultingintissuedegeneration.Lysosomalstoragedisorders(LSDs)areagroupof
inherited diseases characterized by the buildup of undegraded material inside the lysosomes that leads to
autophagic-lysosomal dysfunction. In LSDs, autophagic stress has been associated to mitochondrial accumu-
lation and dysfunction. However, the mechanisms underlying mitochondrial aberrations and how these are
involved in tissue pathogenesis remain largely unexplored. In normal conditions, mitochondrial clearance
occurs by mitophagy, a selective form of autophagy, which relies on a parkin-mediated mitochondrial priming
andsubsequentsequestrationbyautophagosomes.Here,weperformedadetailedanalysisofkeystepsofmito-
phagy in a mouse model of multiple sulfatase deﬁciency (MSD), a severe type of LSD characterized by both
neurological and systemic involvement. We demonstrated that in MSD liver reduced parkin levels resulted in
inefﬁcient mitochondrial priming, thus contributing to the accumulation of giant mitochondria that are located
outside autophagic vesicles ultimately leading to cytochrome c release andapoptotic cell death. Morphological
and functional changes were also observed in mitochondria from MSD brain but these were not directly asso-
ciated with neuronal cell loss, suggesting a secondary contribution of mitochondria to neurodegeneration.
Together, these data shed new light on the mechanisms underlying mitochondrial dysfunction in LSDs and
on their tissue-speciﬁc differential contribution to the pathogenesis of this group of metabolic disorders.
INTRODUCTION
Macroautophagy (usually referred simply as autophagy) is a
catabolic pathway by which parts of the cytoplasm are encap-
sulated in double-membrane vesicles, named autophagosomes,
that are ultimately targeted to lysosomes for degradation (1,2).
Autophagy has been described to be an essential regulatory
mechanism for mitochondrial quality control (3,4). The term
‘mitophagy’ is widely used to designate this speciﬁc form of
autophagy. Initially assumed to be a random process, recent
studies indicate that mitochondrial degradation is a selective
process (5–9).
Mitochondria are recognized to be key regulators of cell
death (10,11). Therefore, proper removal of dysfunctional
mitochondria is essential to preserve cellular homeostasis.
Dysfunctional mitochondria may originate from deleterious
effects of speciﬁc toxic stimuli or by a series of fusion–
ﬁssion events that characterize the mitochondrial life cycle
(12–15). The recognition of aberrant mitochondria, referred
as mitochondrial priming, is based on a PINK1-dependent
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Upon mitochondrial translocation, parkin exerts its E3 ubiqui-
tin ligase activity by ubiquitinating proteins localized on the
outer mitochondrial membrane (OMM) (20,21). Subsequently,
parkin substrates are rapidly recognized by the adaptor protein
p62/SQSTM1, which binds both the cargo and Atg8/LC3 on
the vesicle membrane, thereby targeting mitochondria to
autophagosomes for degradation (22–24). Dysfunctional
parkin and/or defective cargo recognition prevent proper tar-
geting of irreparably damaged mitochondria for mitophagy
resulting in the buildup of toxic, dysfunctional mitochondria,
ultimately leading to cell death (25,26).
Lysosomal storage disorders (LSDs) are a group of  50
inherited metabolic disorders that are caused by defects in
lysosomal function (27,28). The impairment of both endocytic
and autophagic pathways, two degradative membrane trafﬁc
routes to the lysosomes, is now recognized to play an import-
ant role in the pathogenesis of LSDs (29,30). Multiple sulfa-
tase deﬁciency (MSD) is caused by mutations in the
sulfatase modifying factor 1 gene (SUMF1), which is involved
in the posttranslational modiﬁcation of the catalytic site of sul-
fatases (31,32). The lack of conversion of a cysteine residue
into a-formylglycine leads to the absence of all sulfatase
activities and the subsequent accumulation of their speciﬁc
substrates (33). The generation of a mouse model carrying a
null mutation in Sumf1 gene (34) has allowed us to study in
detail the molecular mechanisms underlying the pathogenesis
of this severe type of LSD. We previously demonstrated that
defective fusion between autophagosomes and lysosomes
results in the buildup of mature unfused autophagic vesicles
and in the accumulation of a variety of toxic products
(30,35). The presence of dysfunctional mitochondria was
also observed in MSD-derived mouse embryonic ﬁbroblasts
(MEFs) (30). Altered mitochondria due to autophagic
defects have also been described in other LSDs, namely muco-
lipidosis II (ML II), mucolipidosis III (ML III) (36), mucolipi-
dosis IV (ML IV) (37), GM1-gangliosidosis (GM1) (38,39)
and neuronal ceroid-lipofuscinoses or Batten disease (NCL1)
(40) among others. However, it is not clear how mitochondrial
accumulation is mechanistically linked to autophagic stress. In
particular, it has never been explored whether speciﬁc defects
in mitophagy are the main cause of mitochondrial accumula-
tion in different tissues.
Here, we have analyzed in detail the function of the mito-
phagic machinery in different tissues from a mouse model of
MSD and determined to which extent its deregulation leads
to mitochondrial alterations and tissue pathogenesis in LSDs.
RESULTS
Mitochondria release cytochrome c and trigger cell death
in a tissue-speciﬁc manner in MSD mice
Mitochondria can compromise cell viability leading to tissue
damage. An increase in the permeabilization of the mitochon-
drial membrane, also known as mitochondrial permeability
transition, produces mitochondrial swelling, OMM rupture
and release of pro-apoptotic factors such as cytochrome c.
MSD mice display a multisystemic phenotype that involves
both the central nervous system (CNS) and all main organs
such as the liver. Glycosaminoglycan (GAG) accumulation,
inﬂammation and cell death are detectable as soon as 15
days after birth and progressively increase with age. At 3
months of age, both the liver and CNS pathology are clearly
manifested (30,34,41) (Supplementary Material, Figs S1 and
S2). In particular, we evaluated whether mitochondria
obtained from the brain and liver of MSD mice contributed
to MSD pathology by releasing cytochrome c from the inter-
membrane space. The presence of cytochrome c was not
detected in the cytosolic fractions of MSD brains at any of
the time points analyzed (Fig. 1A). On the contrary, we
observed high levels of cytochrome c in cytosolic fractions
of MSD liver as soon as at 1 month of age.
To test whether the release of cytochrome c detected in the
liver led to cell death, we performed an in situ apoptosis assay
(terminal dUTP nick end labeling—TUNEL) on ﬁxed-parafﬁn
tissue sections of MSD and control mice at 3 months (Fig. 1B).
As expected, few or no TUNEL-positive cells were detected in
brain slices of MSD mice. This result correlates with the
absence of cytochrome c in brain cytosolic fractions
(Fig. 1A). On the other hand, MSD liver sections exhibited a
high concentration of TUNEL-positive cells per area analyzed,
thus suggesting that mitochondria might be the main effectors
of cell death in this tissue.
Abnormal mitochondria accumulate in MSD liver in a
time-dependent manner
We then evaluated whether the mitochondrial release of cyto-
chrome c was related to morphological and functional
changes. We determined the levels of subunit IV of cyto-
chrome oxidase (COX IV), widely used as a marker for quan-
tifying the number of mitochondria (42). COX IV levels were
measured in liver homogenates obtained from MSD (n ¼ 3)
and littermate control mice (n ¼ 3) by western blot analysis.
As shown in Figure 2A, signiﬁcant changes were only
observed at advanced stages, thus indicating that the accumu-
lation of mitochondria is a progressive process in liver
pathogenesis.
Next, we evaluated whether these mitochondria were mor-
phologically and functionally altered. We used the AnalySIS
software to measure the diameter of mitochondria in liver
ultrathin sections. Mitochondria of MSD appeared signiﬁcantly
larger (giant) than in controls, thus indicating that morpho-
logical changes precede the accumulation of mitochondria in
MSD liver (Fig. 2B).
Finally, we tested the functionality of liver mitochondria.
We assessed the integrity of the mitochondrial membrane by
using JC-1, a ﬂuorescent cationic dye that accumulates in
mitochondria with intact electrochemical gradient. We iso-
lated mitochondria from livers of MSD (n ¼ 3) and control
mice (n ¼ 3) and measured the incorporation of JC-1. A
decrease in mitochondrial membrane potential was observed
as soon as 1 month and became evident at advanced stages
of the pathology (Fig. 2C). As mitochondria are the main
source of energy, we measured the amount of adenosine tri-
phosphate (ATP) in mitochondrial fractions. Isolated mito-
chondria from MSD liver displayed a striking decrease in
ATP content (Fig. 2D).
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alterations and morphological changes appear simultaneously
and are both associated to the release of cytochrome c and
to liver pathology (Table 1).
Mitochondria accumulate outside autophagosomes
Mitophagy recycles abnormal mitochondria through their tar-
geting and encapsulation by autophagosomes. To assess the
functionality of this process, we analyzed the morphology
and content of autophagosomes by electron microscopy. In
MSD mice, qualitative analysis of liver ultrathin sections
revealed the presence of autophagic vesicles along with
fuzzy content. The number of vesicles with no-recognizable
structures, called ‘empty’ autophagosomes, increased over
time, thus suggesting a progressive impairment of autophagic
cargo sequestration (Fig. 3A).
To conﬁrm these results, we assessed mitochondrial seques-
tration in both control and MSD MEFs that transiently
overexpress GFP-LC3 (autophagic marker) and DsREDmito
(mitochondrial marker) plasmids. Cells were treated with car-
bonyl cyanide 3-chlorophenylhydrazone (CCCP; 20 mM, 20 h),
a mitochondrial-uncoupling agent that induces membrane de-
polarization and promotes mitochondrial elimination by autop-
hagy. We analyzed mitochondrial morphology in both treated
and untreated cells to ensure that CCCP was able to induce
mitochondrial fragmentation in our cell line. Cells were clas-
siﬁed in three different categories according to the mitochon-
drial morphology visualized with DsREDmito: ‘networked’,
that included cells with the typical ﬁlamentous-elongated
mitochondrial morphology; ‘fragmented’, that include cells
with mitochondria showing a clear round-shaped morphology;
and ‘intermediate’, that include cells with an undeﬁned pattern
(some networked and some fragmented). In steady-state condi-
tions, a high percentage of MSD cells presented an intermedi-
ate morphology, whereas the great majority of control cells
had a networked pattern. Upon CCCP treatment, mitochondria
from both MSD and control cells appeared fragmented, thus
indicating that CCCP is able to promote membrane depolar-
ization in both types of cells (Fig. 3B).
Figure 1. Mitochondria release cytochrome c and trigger cell death in MSD liver. (A) Anti-cytochrome c immunoblots of subcellular fractions (c, cytosol; m,
mitochondria) obtained from the whole brain and liver from MSD (n ¼ 4) and control mice (n ¼ 4) at P15, 1 month and 3 months. COX IV was used as mito-
chondrial loading control. In the liver, levels of cytochrome c were quantiﬁed in each cytosolic fraction and expressed as the average percentage in terms of fold
changes (bottom); ∗∗P , 0.01. (B) TUNEL analysis on ﬁxed-parafﬁn brain and liver sections of MSD and control mice at 3 months. Images were acquired with
the 20× magniﬁcation. Positive controls were obtained by treating tissue sections with DNAase I. TUNEL-positive cells were stained in green, and nuclei were
labeled with 4′,6-diamidino-2-phenylindole (DAPI, blue).
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ed (NT) and CCCP-treated MSD and control MEFs. In control
cells, CCCP treatment resulted in a signiﬁcant increase in
LC3-mito co-localization. Inversely, CCCP treatment did not
result in any increase in LC3-mito co-localization in MSD
cells, thus conﬁrming a defect in mitochondrial sequestration
by autophagosomes (Fig. 3C).
These results indicate that autophagosomes are not able to
encircle depolarized mitochondria in MSD.
Impaired mitochondrial priming in MSD is due to
insufﬁcient parkin-mediated mitochondrial ubiquitination
Mitochondrial targeting to autophagosomes relies on parkin-
mediated ubiquitination of OMM proteins. This step is
crucial for proper mitochondrial recognition and degradation
by autophagy. Therefore, we analyzed the efﬁciency of parkin-
mediated ubiquitination in MSD mice. To date, two different
OMM proteins have been described as parkin substrates for
mitochondrial autophagy: VDAC1 (20) and MFN1 (21).
However, the involvement of other OMM proteins cannot be
excluded. For this reason, we determined the total amount of
ubiquitinated proteins in mitochondrial extracts obtained
from livers of MSD (n ¼ 4) and control mice (n ¼ 4)
(Fig. 4A). Reduced levels of ubiquitinated proteins per mito-
chondria (ATPase b content) were detected in MSD livers
compared with controls, suggesting that incomplete/partial
ubiquitination of mitochondrial proteins leads to inefﬁcient
cargo recognition and autophagosome mistargeting.
We reasoned that incomplete mitochondrial ubiquitination
may be due to either inefﬁcient parkin translocation and/or
to reduced levels of parkin protein/activity. To address these
Figure 2. Dysfunctional giant mitochondria accumulate in a time-dependent manner in MSD liver. (A) Levels of COX IV in liver total lysates of MSD (n ¼ 3)
and control (n ¼ 3) mice at P15, 1 month and 3 months. The COX IV/actin ratio is expressed in terms of fold changes and represents an average value; ∗∗P ,
0.01. (B) Analysis of mitochondrial size (diameter) using the AnalySIS software in liver ultrathin sections (70 nm) from MSD and control mice at 1 month and 3
months. Average number of mitochondria analyzed: control 1 month ¼ 43, MSD 1 month ¼ 56, control 3 months ¼ 60, MSD 3 months ¼ 127. Values are
expressed in nm (scale bar ¼ 400 nm). ANOVA P-value ¼ 1.27 × 10
213, ∗∗P , 0.01. (C) Measurement of JC-1 ﬂuorescence (FLU) per milligram (mg) of
protein in isolated mitochondria from MSD (n ¼ 3) and control (n ¼ 3) mice at 1 month and 3 months. Values are expressed in terms of fold changes compared
with control. ANOVA P-value ¼ 0.048, ∗P , 0.05. (D) Analysis of ATP content per microgram (mg) of protein in isolated mitochondria from MSD (n ¼ 3) and
control (n ¼ 3) mice at 1 month and 3 months. Values are expressed in terms of fold changes compared with control. ANOVA P-value ¼ 4.81 × 10
23, ∗P ,
0.05, ∗∗P , 0.01.
Table 1. Mitochondrial morphology and function in MSD liver
Mitochondria Number Morphology Functionality Cytochrome c
release
Liver pathology
P15 ¼ –– N o
1 month ¼ Giant ¼JC-1FLU , ATP
content
Yes
3 months . Giant ,JC-1 FLU , ATP
content
Yes
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DsREDmito plasmids in MSD and control MEFs, which
were then incubated in the presence/absence of the mitochon-
drial uncoupler CCCP (20 mM, 20 h). As shown in Figure 4B,
parkin localization was entirely cytoplasmic in both MSD and
control untreated cells. Upon CCCP treatment, a massive de-
polarization of mitochondria induced the translocation of
large amounts of parkin in both control and MSD MEFs, indi-
cating that parkin is properly recruited to depolarized mito-
chondria in MSD cells.
Once we conﬁrmed the proper recruitment of parkin in
vitro, we evaluated parkin levels in liver total homogenates
obtained from MSD (n ¼ 4) and control mice (n ¼ 4). We
found that parkin levels were strongly reduced in MSD liver
(Fig. 5A). Similar data were obtained in mitochondrial frac-
tions (Fig. 5B).
Our results indicate that despite parkin is able to efﬁciently
translocate to mitochondria, its levels are strongly reduced in
MSD liver, thus resulting in an incomplete mitochondrial
ubiquitination. Reduced parkin levels are likely due to
enhanced degradation/decrease stability as no signiﬁcant dif-
ferences were observed in Park2 relative expression (Fig. 5C).
Autophagy induction is inhibited in MSD liver
We monitored the levels of LC3-II in MSD liver at different
time points and found that the LC3-II/actin ratio was signiﬁ-
cantly increased compared with control (Fig. 6A). These
data are consistent with the impairment of autophagosome
maturation already reported in MSD (30,35). Interestingly,
LC3-II accumulation was not associated with the induction
of beclin-1 (BECN-1) at this stage of pathology. On the con-
trary, beclin-1 protein levels were reduced, whereas its mRNA
levels remained unaltered (Fig. 6B and C).
Therefore, autophagy is downregulated in MSD liver, which
might contribute to the mistargeting and subsequent accumu-
lation of mitochondria by limiting the formation of new autop-
hagic vesicles.
Figure 3. Mitochondria accumulate outside autophagosomes. (A) Electron microscopy analysis of autophagosome (AV) content in liver ultrathin sections
(70 nm) at different ages: P15, 1 month and 3 months. Qualitatively, autophagosomes of MSD liver are classiﬁed into two categories: empty AVs (white
arrowheads) or ﬁlled AVs (black arrows) (scale bar ¼ 400 nm). Values are expressed as percentages of the total number of autophagosomes. (B) Analysis of
mitochondrial morphology in untreated (NT) and CCCP-treated MSD and control MEFs. Cells were classiﬁed into three categories: networked (ANOVA
P-value ¼ 3.91 × 10
212), intermediate (ANOVA P-value ¼ 1.24 × 10
23) and fragmented (ANOVA P-value ¼ 6.77 × 10
27). Results are expressed as the per-
centage of cells in each category; ∗P , 0.05; ∗∗P , 0.01. (C) Confocal images (63×) of untreated (NT) and CCCP-treated (20 mM, 20 h) MSD and control MEFs
co-expressing GFP-LC3 (green) and DsREDmito (red) plasmids. The zoomed region is indicated by a white square. Co-localization index is expressed with the
M1 (Mander’s) coefﬁcient. ANOVA P-value ¼ 0.33, ∗P , 0.05.
1774 Human Molecular Genetics, 2012, Vol. 21, No. 8Mitochondrial alterations in MSD brain are not associated
with defects in mitochondrial priming machinery
As reported in Figure 1, mitochondria from MSD brain do not
release cytochrome c. Further morphological and functional
analyses revealed that, in contrast to what observed in liver,
mitochondria became fragmented (Fig. 7A) and showed
reduced membrane integrity and ATP content (Fig. 7B).
However, these changes were not as evident as those observed
in the liver, indicating a milder mitochondrial phenotype. No
alterations in the number of mitochondria were detected at
any of the time points analyzed (Fig. 7C), suggesting an efﬁ-
cient mitochondrial removal in this tissue. In fact, the analysis
of the content of autophagosomes showed that the percentage
of empty mitochondria represented a small fraction and
remained constant over time (Fig. 7D). Consistently, we did
Figure 4. Incomplete ubiquitination is not due to impaired parkin translocation to mitochondria. (A) Anti-ubiquitin immunoblots of liver mitochondrial extracts
obtained from MSD (n ¼ 4) and control (n ¼ 4) mice at 1 month and 3 months. ATPase b was used as mitochondrial loading control and results were expressed
as the fold changes of the ubiquitin/ATPase b ratio; ∗P , 0.05. (B) Confocal images (63×) of untreated (NT) and CCCP-treated (20 mM, 20 h) MSD and control
MEFs co-expressing GFP-parkin (green) and DsREDmito (red) plasmids. The zoomed region is indicated with a white square. Co-localization is expressed as the
M1 (Mander’s) index. ANOVA P-value ¼ 0.158, ∗∗P , 0.01.
Figure 5. Reduced parkin levels are not a consequence of low Park2 expression. (A) Parkin total levels in liver homogenates from MSD (n ¼ 4) and control (ctrl)
mice (n ¼ 4) at 1 month and 3 months. Relative levels are expressed as the Parkin/actin ratio in terms of fold changes; ∗∗P , 0.01. (B) Parkin distribution in
subcellular fractions (c, cytosol; m, mitochondria) obtained from liver of MSD (n ¼ 4) and control (ctrl) mice (n ¼ 4) at 3 months. Mitochondrial levels were
normalized with COX IV (mitochondrial loading control) and the Parkin/COX IV ratio was expressed as fold changes; ∗P , 005. (C) Park2 mRNA relative
levels in MSD liver (n ¼ 3) at 1 month and 3 months obtained by quantitative PCR. Values are expressed as fold changes compared with control; ANOVA
P-value ¼ 0.2.
Human Molecular Genetics, 2012, Vol. 21, No. 8 1775not ﬁnd any alteration in the levels of ubiquitinated proteins in
brain mitochondrial fractions (Fig. 7E). Moreover, parkin total
levels were normal, thus conﬁrming the proper functioning of
the mitochondrial priming machinery in MSD brain.
DISCUSSION
LSDs are metabolic disorders due to mutations in the genes
encoding speciﬁc proteins involved in lysosomal function,
resulting in the accumulation of undegraded material. The
degree of severity of the disease depends on the type of
storage material and the site of accumulation that generally
affects vital organs such as the brain and liver (27). In
LSDs, the correlation between enzyme deﬁciency and the
type of storage are well characterized. However, the molecular
pathways leading to LSD pathology remain largely unex-
plored. LSDs have been recently listed as autophagy disorders.
In fact, defects in autophagosome formation and maturation
have been extensively associated to LSD pathogenesis
(30,35–38,40,43). However, whether any of the steps of mito-
phagy is defective and whether this may be responsible for the
mitochondrial phenotype has never been addressed in LSDs.
Moreover, how defects in the autophagic pathway are linked
to cell death and tissue damage has not been elucidated yet.
In this study, we demonstrate for the ﬁrst time that the
accumulation of mitochondria observed in LSDs is not a
mere consequence of defective autophagosome–lysosome
fusion but involves a more speciﬁc mechanism that mediates
mitochondrial priming and targeting to autophagosomes. The
analysis of both parkin expression and activity in two affected
tissues of MSD mice revealed tissue-speciﬁc defects in MSD
mice. In fact, reduced parkin protein levels were exclusively
detected in MSD liver samples and not in MSD brains at all
time points analyzed. In line with this, the reduction of
parkin resulted in an incomplete/partial ubiquitination of mito-
chondrial proteins on the OMM despite the presence of an
efﬁcientparkin translocation,asshown inparkin-overexpressing
MSD MEFs. As no differences in the Park2 mRNA relative
expression were detected, we speculate that low parkin
levels in MSD liver may be due to enhanced parkin degrad-
ation/reduced stability. Interestingly, it has been reported
that parkin degradation is controlled by another E3 ubiquitin
ligase called Nrdp1, whose over-expression has been
described to signiﬁcantly reduce the half-life of parkin from
5 to 2.5 h (44). Further studies must be performed in order
to understand the real causes of parkin reduction and
whether it can be directly correlated to lysosomal dysfunction.
A defective sequestration of mitochondria by autophago-
somes was observed as a consequence of impaired mitochon-
drial priming. A high percentage of empty vesicles was
Figure 6. Autophagy is inhibited at advanced stages of MSD liver pathology. (A) LC3 immunoblots on total liver homogenates from MSD (n ¼ 3) and control
mice (n ¼ 3) at P15, 1 month and 3 months. Autophagosome accumulation is expressed as the fold change of the LC3-II/actin ratio compared with control;
∗∗P , 0.01, ∗∗∗P , 0.005. (B) Levels of BECN-1 were measured in liver extracts from MSD (n ¼ 3) and control mice (n ¼ 3) at P15, 1 month and 3
months. The BECN-1/actin ratio is expressed as fold changes; ∗∗P , 0.01. (C) Becn1 mRNA levels were determined by real-time PCR in liver samples
(n ¼ 3) at 3 months.
1776 Human Molecular Genetics, 2012, Vol. 21, No. 8Figure 7. Altered mitochondria are a late-onset feature of MSD brain pathology. (A) Analysis of mitochondrial size (diameter) using the AnalySIS software in
brain (cerebellum area) ultrathin sections (70 nm) from MSD and control mice at 1 month and 3 months. Average number of mitochondria analyzed: control 1
month ¼ 60, MSD 1 month ¼ 79, control 3 months ¼ 62, MSD 3 months ¼ 158. Values are expressed in nm (scale bar ¼ 400 nm). ANOVA P-value ¼ 6 ×
10
23, ∗∗P , 0.01. (B) Top: measurement of JC-1 ﬂuorescence (FLU) per milligram (mg) of protein in isolated mitochondria from MSD (n ¼ 3) and control
(n ¼ 3) mice at 1 month and 3 months, ANOVA P-value ¼ 0.065. Bottom: analysis of ATP content per microgram (mg) of protein in isolated mitochondria
from MSD (n ¼ 3) and control (n ¼ 3) mice at 1 month and 3 months, ANOVA P-value ¼ 0.039. Values are expressed in term of fold changes compared
with control; ∗P , 0.05. (C) Levels of COX IV in brain total lysates of MSD (n ¼ 3) and control (n ¼ 3) mice at P15, 1 month and 3 months. The COX
IV/actin ratio is expressed as fold changes. (D) Electron microscopy analysis of autophagosome (AV) content in brain ultrathin sections (70 nm) at different
ages: P15, 1 month and 3 months. Qualitatively, autophagosomes of MSD tissues are classiﬁed into two categories: empty AVs or ﬁlled AVs (black arrows)
(scale bar ¼ 400 nm). Values are expressed as percentages of the total number of autophagosomes. (E) Anti-ubiquitin immunoblots of brain mitochondrial
extracts obtained from MSD (n ¼ 4) and control mice (n ¼ 4) at 1 month and 3 months. ATPase b was used as mitochondrial loading control and values
were expressed as the ubiquitin/ATPase b ratio (fold changes). (F) Parkin total levels in brain homogenates from MSD (n ¼ 4) and control mice (n ¼ 4) at
1 month and 3 months. Values are expressed as the Parkin/actin ratio (fold changes).
Human Molecular Genetics, 2012, Vol. 21, No. 8 1777reported in MSD livers, whereas only a small percentage of
autophagosomes appeared empty in the brain. Co-localization
analysis of GFP-LC3/DsREDmito in MSD and control MEFs
conﬁrmed the defective turnover of mitochondria by autopha-
gic vesicles. The pathologic accumulation of autophagosomes
was previously reported in MSD brain but not in the liver (30).
Here, we show that the accumulation of autophagosomes is a
hallmark of liver pathology in MSD mice. Moreover, we
observed that the accumulation of autophagic vesicles in this
tissue is due to defective autophagosome maturation and not
to an enhanced induction of autophagy. Accordingly,
unaltered levels of Beclin-1 were observed at P15 and
1-month MSD liver homogenates. Interestingly, at advanced
stages of the pathology, Beclin-1 protein levels but not
mRNA levels appeared reduced. In fact, it has been previously
described that the mitochondrial proteins Bcl-2 and Bcl-XL
negatively regulate autophagy by binding to Beclin-1 (45).
Therefore, we hypothesize that autophagy inhibition together
with a defect in autophagosome maturation may contribute
to the phenotype observed in the liver by limiting the avail-
ability of new autophagic vesicles.
As a consequence of impaired mitophagy, non-recycled
mitochondria accumulate in MSD liver in a time-dependent
manner. Further morphological analysis of MSD livers
revealed an increase in mitochondrial size as soon as P15.
Mitochondrial enlargement can be a consequence of (1)
defective ﬁssion, (2) a high rate of fusion and (3) impaired
mitophagy. However, in the majority of cases, the presence
of giant mitochondria is a consequence of defective mitochon-
drial turnover (15,46). Functional assays based on the meas-
urement of ATP production and membrane integrity showed
that mitochondria from MSD liver had reduced ATP content
and low membrane potential. Dysfunctional mitochondria
are potentially harmful for cell viability. In fact, the release
of pro-apoptotic proteins, such as cytochrome c, was observed
in MSD livers as soon as at 1 month of age (Table 1). The
detection of a high number of TUNEL-positive cells con-
ﬁrmed the contribution of non-removed dysfunctional mito-
chondria to liver pathology in MSD mice. Contrary to what
observed in the liver, mitochondrial alterations in MSD
brain were milder and appeared at later stages of the path-
ology. Furthermore, although loss of Purkinje cells has been
described in MSD mice as soon as 2 months (34), neither cyto-
chrome c release nor TUNEL-positive cells were detected at
any of the stages analyzed. Therefore, mitochondrial morpho-
logical and functional changes cannot be directly correlated
with defects in the mitochondrial priming machinery but
may be associated to different pathogenic cascades and/or
toxic stimuli.
The differences observed between the brain and liver may
be explained by different energetic requirements and organ
cell composition. Neurons are highly dependent on ATP pro-
duction and consume more energy than other cells for their
metabolism. Moreover, mitochondria play an important role
in synaptic maintenance. For this reason, post-mitotic cells
are expected to be particularly sensitive to changes in mito-
chondrial activity and therefore, mitochondrial turnover
would reasonably be a very tightly controlled event in
neurons through alternative quality control mechanisms.
However, in all brain experiments, we used whole brain
samples, so it may be possible that some region-speciﬁc differ-
ences may have been masked. Therefore, we cannot exclude
that a more severe mitochondrial phenotype may occur in spe-
ciﬁc brain areas.
This study demonstrates a tissue-speciﬁc impairment of
mitochondrial priming machinery in LSDs, resulting in the
accumulation of dysfunctional mitochondria ultimately leading
to cell death. These tissue-speciﬁc pathogenic mechanisms
should be taken in consideration when developing therapeutic
strategies aimed at treating brain and systemic lesions in
LSDs.
MATERIALS AND METHODS
Antibodies, plasmids and reagents
The antibodies used in this work were: rabbit anti-COX IV (IB
1:1000,#4844,CellSignalingTechnology,Boston,MA,USA),
mouse anti-Cytochrome c (IB 1:1000, Cat. 556433, BD Phar-
mingen, NJ, USA), rabbit anti-LC3 (IB 1:1000, NB100-2331,
Novus Biologicals, CO, USA), mouse anti-Parkin (IB 1:1000,
#4211, Cell Signaling Technology, NJ, USA), rabbit anti-
Ubiquitin (IB 1:500, Z0458, Dako Cytomation, CA, USA),
mouse anti-ATPase b subunit (IB 1:10000, ab14730, Abcam,
Cambridge, UK), rabbit anti-BECN1 (IB 1:1000, sc11427,
Santa Cruz Biotech, CA, USA.) and mouse anti-b-actin
(1:10000, A1978, Sigma-Aldrich, MO, USA). Secondary
horseradish peroxidase-conjugated antibodies (anti-rabbit
1:3000andanti-mouse1:5000)werefromGEHealthcare(UK).
Plasmids GFP-LC3 (37), DsREDmito and GFP-myc-Parkin
were a kind gift of Prof. Luca Scorrano (University of Geneva)
and Prof. Wolfdieter Springer (University of Tu ¨bingen),
respectively.
Reagents: CCCP (C2759) was from Sigma-Aldrich. For
plasmidtransfections,weusedLipofectamine2000(Invitrogen).
Animal experiments
Mice were anesthetized with avertin (20 ml/g weight) and then
perfused with phosphate-buffered saline (PBS) before tissue
collection.
Animal use and analyses were conducted in accordance
with the guidelines of the Animal Care and Use Committee
of Cardarelli Hospital in Naples and authorized by the
Italian Ministry of Health.
Quantiﬁcation of GAGs
Liver tissue samples were mechanically homogenized in water
using the TissueLyser equipment (Qiagen, Germany). Proteins
were quantiﬁed by the Bradford method (Biorad, CA, USA),
and samples were diluted to concentrations equal to 200 mg/
ml of total proteins to run on the assay. Samples were then
incubated with dimethylmethylene blu–Tris/formate, and col-
orimetry was immediately measured in an enzyme-linked im-
munosorbent assay reader plate at 520 nm. Several
concentrations of dermatan sulfate were used to calculate the
standard curve.
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TotalRNAwasextractedfromtissueusingtheRNeasy
wKitand
retrotranscribed with QuantiTect
w Reverse Transcription Kit
(Qiagen) following the manufacturer’s instructions. Ampliﬁca-
tionofcDNAwasperformedusingtheSYBRGreenIMasterfor
LightCycler
w480(Roche,Switzerland).Primersequenceswere
designed using the GenScript Primer Design tool GenScript
Primer Design tool (https://www.genscript.com/ssl-bin/app/p
rimer). b-Actin was used as a housekeeping gene.
Protein extraction for immunoblotting
For total protein extracts, tissue samples were homogenized in
cold lysis buffer [50 mM Tris–HCl, pH 7.4, 150 mM NaCl,
1m M ethylenediaminetetraacetic acid (EDTA), 1% Triton
X-100, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium
deoxycholate] in the presence of protease inhibitors (Sigma).
Mechanical disruption of samples was performed using the
TissueLyser equipment (Qiagen). Homogenates were incu-
bated on ice for 30 min and then centrifuged at maximum
speed to eliminate cellular debris. Proteins were quantiﬁed
by the Bradford method (Biorad).
Subcellular fractionation was carried out by homogenization
of tissue samples in an ice-cold hypotonic buffer [300 mM
sucrose, 10 mM4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid (HEPES), pH 7.4, 200 nM EDTA] in the presence of prote-
ase inhibitors (Sigma). Samples were mechanically disrupted
with micropestles (Eppendorf, Germany) and then passed
through a 20G- and a 26G-needle for several times. The same
amount of protein (1 mg) was processed in an equal volume of
bufferforallsamples.Thesupernatantoftheﬁrstcentrifugation
(5 min, 600 g) was further centrifuged at 16 000g for 15 min.
Supernatants were stored as the cytosolic fraction. Pellets
were washed in buffer and re-centrifuged. The resultant
pellets (mitochondria) were resuspended in the same volume
of lysis buffer. For the analysis of cytochrome c release by im-
munoblotting, same amounts of samples were loaded in a
SDS–polyacrylamide gel electrophoresis (PAGE) gel.
Sodium dodecyl sulfate—polyacrylamide gel
electrophoresis
Same amounts of protein (20–50 mg) were loaded in an SDS–
PAGE gel and run was performed at 80 V for at least 3 h. Blot-
ting was performed at 48C overnight at a constant voltage
(30 V). Membranes were blocked in Tris-buffered saline/T
5% milk for 1 h at room temperature (RT). Primary antibody
was then incubated for 1–2 h at RT followed by the incuba-
tion with an HPR-conjugated secondary antibody (1 h at
RT). Detection was performed using the ECL substrate
(Pierce).
Electron microscopy
Tissue samples were ﬁxed in 1% glutaraldehyde in 0.2 M
HEPES buffer and post-ﬁxed in OsO4 and uranyl acetate.
After dehydration in graded series of ethanol, tissue samples
were cleared in propylene oxide, embedded in Epoxy resin
(Epon 812) and polymerized at 608C for 24 h. For each
sample, ultrathin sections (70 nm) were cut with a Leica EM
UC6 ultramicrotome. Electron microscopy images were
acquired using a FEI Tecnai-12 electron microscope equipped
with an ULTRA VIEW CCD digital camera (FEI, Eindhoven,
the Netherlands). Measurement of mitochondrial size (diam-
eter) was performed using the AnalySIS software (Soft
Imaging Systems GmbH, Munster, Germany).
Mitochondrial functional assays
Tissue mitochondria were isolated following the Mitochondria
Isolation Kit protocol (MITOISO1; Sigma). Mitochondrial
membrane potential was determined by incubation of isolated
mitochondria with the JC-1 dye according to the manufac-
turer’s instructions (Sigma). ATP content was measured
using the ATP Determination Kit (A22066; Invitrogen,
CA, USA).
Confocal microscopy
MEFs were transfected with GFP-LC3, DsREDmito and
GFP-myc-Parkin. Twenty-four hours after transfection, cells
were treated with CCCP (20 mM) for 20 h. After treatment, cells
were gently washed with PBS, ﬁxed in 4% paraformaldehyde
(PFA) and mounted with vectashield (Vector Labs, CA, USA).
Images were taken using the 63×/1.4 Oil DiC M27 object-
ive on a Zeiss LSM 710 confocal microscope. Laser lines at
488 nm (GFP-LC3, GFP-Parkin) and 561 nm (DsREDmito)
were used.
Co-localization analysis was performed using the JaCoP
plugin (just another co-localization plugin) for Image J. The
results were expressed as the M1 coefﬁcient (Mander’s).
TUNEL assay
Parafﬁn-embedded tissues were sectioned (7 mM) in a Leica
RM165 microtome and ﬁxed in 4% PFA. Apoptotic nuclei
were detected using the In Situ Cell Death Detection Kit
(Roche) following the manufacturer’s instructions.
Data analysis
All blots were quantiﬁed using the Image J software, and
results were analyzed by Student’s t-distribution. An analysis
of variance (ANOVA) test (two-way ANOVA) was also
used for mitochondrial morphological and functional assays,
real-time PCRs and co-localization experiments. Results
were expressed as the average of three or more independent
experiments. A P-value ,0.05 was considered statistically
signiﬁcant.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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